Tricida (TCDA) Stock Analysis
NASDAQHealthcareBiotechnology
What Tricida does
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Key metrics
ETFs linked to TCDA
Broad-market and Healthcare sector ETFs an investor holding Tricida is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how TCDA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze TCDA in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Tricida?
- Tricida trades under the ticker TCDA on NASDAQ.
- Which exchange is TCDA listed on?
- TCDA is listed on NASDAQ.
- What sector does Tricida operate in?
- Tricida is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze TCDA in a portfolio?
- PortView shows TCDA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.